EXACT Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

EXACT Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-13.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-13.7%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth

Sep 15

EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans

Jan 31

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

Aug 21

We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate

May 21

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: EXTX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: EXTX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

EXACT Therapeutics Piyasaya Karşı Temettü Getirisi

EXTX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (EXTX)	n/a
Pazarın Alt %25'i (NO)	3.3%
Pazarın En İyi %25'i (NO)	7.6%
Sektör Ortalaması (Biotechs)	1.6%
Analist tahmini (EXTX) (3 yıla kadar)	n/a

Önemli Temettü: EXTX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, EXTX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: EXTX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: EXTX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

EXACT Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

EXACT Therapeutics AS Announces Full Focus on Phase 2 Pancreatic Cancer Trial

New major risk - Share price stability

Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?

New minor risk - Financial data availability

New minor risk - Share price stability

EXACT Therapeutics AS to Report Fiscal Year 2023 Results on Apr 18, 2024

New minor risk - Shareholder dilution

Chair of the Board recently sold kr300k worth of stock

EXACT Therapeutics AS has completed a Follow-on Equity Offering in the amount of NOK 24.999996 million.

EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023

EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose Escalation

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE Study

EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study

No independent directors

EXACT Therapeutics AS Announces Management Changes

We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash Wisely

No independent directors

Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical Trial

No independent directors

EXACT Therapeutics AS, Annual General Meeting, Jun 09, 2023

Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn Situation

No independent directors

Norwegian Research Council Awards EXACT Therapeutics AS Exact-Tx NOK 16 Million to Support the Research of Immunotherapy Responses in Solid Tumours with Acoustic Cluster Therapy

No independent directors

No independent directors

EXACT Therapeutics AS Announces Appointment of Amir Snapir as Chief Medical Officer, Effective 21 September 2022

Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In Growth

No independent directors

EXACT Therapeutics AS Appoints John Edminson as Chief Financial Officer, Effective 1 October 2022

No independent directors

EXACT Therapeutics as Announces Board Changes

No independent directors

EXACT Therapeutics AS Announces Resignation of Dr. Jean-Claude Provost as Board Member

No independent directors

EXACT Therapeutics AS Appoints Per Walday as Chief Executive Officer

EXACT Therapeutics AS Announces Clinical Trial Update

No independent directors

EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth Plans

Executive Chairperson recently bought kr71k worth of stock

Director Hans Klouman has left the company

We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business Growth

Deputy Chairperson recently bought kr208k worth of stock

EXACT Therapeutics AS Announces Clinical Trial Update

We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn Rate

Chief Financial Officer has left the company

EXACT Therapeutics AS Announces Executive Changes

Exact Therapeutics Announces Innovative Probe Development Collaboration with GE Healthcare

New 90-day low: kr25.50

New 90-day low: kr31.50

EXACT Therapeutics AS has completed an IPO in the amount of NOK 155.010604 million.

EXACT Therapeutics AS to Report Fiscal Year 2019 Results on Apr 29, 2021

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin